Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

18:26 EST 21st February 2018 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [73 Associated News Articles listed on BioPortfolio]

AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity

AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity

Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis

Novartis International AG / Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis . Processed and transmitted by Nasdaq Corporate Solutions. The i...

Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

Novartis International AG / Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis . Processed and transmitted by ...

Sienna Biopharmaceuticals Inc SNNA Medical Equipment Deals and Alliances Profile [Report Updated: 09022018] Prices from USD $250

SummarySienna Biopharmaceuticals Inc Sienna Biopharmaceuticals is a biopharmaceutical company that develops innovation therapies for inflammatory skin conditions and aesthetic conditions. It offers to...

Clarify Medical to Launch First Smartphone-Connected Home Phototherapy System

Clarify Medical will introduce the Clarify Medical® Home Light Therapy System, an FDA-cleared home phototherapy system for the treatment of psoriasis, vitiligo, and eczema at the...

Congress Is About to Let Insurers Abandon Their Financial Commitment to Medicare Part D

Statement from the Global Healthy Living Foundation in response to the Bipartisan Budget Act of 2018 Part D provision Despite the fact that insurance companies are now the mos...

Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis

Novartis International AG / Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis . Processed and transmitted by Nasdaq Corporate Solutions. The is...

Global $21.4 Billion Psoriasis Drugs Market Analysis 2016-2022 by Therapeutic Class, Treatment and Segment Forecasts - ResearchAndMarkets.com

The "Psoriasis Drugs Market Analysis by Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), by Treatment (Topicals, Systemic,...

BRIC Market Report Suite for Immunology Drugs 2017 - ResearchAndMarkets.com

The "BRIC Market Report Suite for Immunology Drugs 2017 - MedSuite" report has been added to ResearchAndMarkets.com's offering. Besides the typical market d...

Europe Immunology Drugs Market Report Suite 2017 - ResearchAndMarkets.com

The "Europe Market Report Suite for Immunology Drugs 2017 - MedSuite" report has been added to ResearchAndMarkets.com's offering. Besides the typical market...

Events [0 Results]

None

Companies [22 Associated Companies listed on BioPortfolio]

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

Clinical Trials [604 Associated Clinical Trials listed on BioPortfolio]

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if t...

Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis

This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate...

Comparative Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin

The project topic consists on re-conciliating the fine tuners of the gene expression "microRNAs" and the immunopathogenic occasions responsible for skin disorders in context of skin infect...

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

This is a randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of PPC-06 (tepilamide fumarate) extended release in subjects with moder...

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be adm...

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis

This study is a prospective, single blinded, randomized, pilot study to To compare the effectiveness and safety profile of oral versus subcutaneous route of administration of methotrexate ...

Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis

This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients wit...

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.

PubMed Articles [275 Associated PubMed Articles listed on BioPortfolio]

Reply to: "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials".

In response to Lebwohl et al, "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials".

Psoriasis in the perspective of predictive, preventive participatory and personalized medicine.

Incidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children.

Glucocorticoids are widely used for immunosuppression in autoimmune diseases. After the resolution of hypercortisolemia, the immune system recovers allowing for autoimmune diseases to manifest. Here w...

Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.

In the original publication, section 5, paragraph 1 was incorrectly published.

Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment.

Treatment optimization with secukinumab 150 mg for moderate-to-severe psoriasis in clinical practice: a single-center open-label 52-week study.

Major role for TRPV1 and InsP3R in PAR-2-elicited inflammatory mediator production in differentiated human keratinocytes.

Proteinase-activated receptor-2 (PAR-2) activation in basal keratinocytes stimulates inflammation via the Ca-dependent production of mediators such as interleukin (IL)-1β, tumor necrosis factor (TNF)...

Molecular action of isoflavone genistein in the human epithelial cell line HaCaT.

Due to its strong proliferation-reducing effects on keratinocytes, and also anti-inflammatory properties, the isoflavone genistein has already been proposed as a possible antipsoriatic compound. As th...

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study).

Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe ps...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

review and buy Moderate-to-Severe Plaque Psoriasis market research data and corporate reports here

Channels Quicklinks